Evidence map›Paper›PMID 35750669›Full record

ArticleNature communications2022

DNA damage-induced transcription stress triggers the genome-wide degradation of promoter-bound Pol II.

Barbara Steurer, Roel C Janssens, Marit E Geijer, Fernando Aprile-Garcia, Bart Geverts, Arjan F Theil, Barbara Hummel, Martin E van Royen, Bastiaan Evers, René Bernards and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. DNA damage and repair in cardiomyopathy: mechanisms and therapeutic opportunities.American journal of physiology. Heart and circulatory physiology · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Barbara Steurer *Department of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Roel C Janssens *Department of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Marit E GeijerDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0001-9453-6997
Fernando Aprile-GarciaMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.ORCID 0000-0002-5133-0857
Bart GevertsDepartment of Pathology, Optical Imaging Centre, Erasmus MC, Rotterdam, The Netherlands.
Arjan F TheilDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Barbara HummelMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Martin E van RoyenDepartment of Pathology, Optical Imaging Centre, Erasmus MC, Rotterdam, The Netherlands.ORCID 0000-0002-6814-0996
Bastiaan EversOncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
René BernardsOncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0001-8677-3423
Adriaan B HoutsmullerDepartment of Pathology, Optical Imaging Centre, Erasmus MC, Rotterdam, The Netherlands.
Ritwick SawarkarMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Jurgen MarteijnDepartment of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. j.marteijn@erasmusmc.nl.ORCID 0000-0001-9321-518X
Erasmus MC · NLMax Planck Institute of Immunobiology and Epigenetics · DEThe Netherlands Cancer Institute · NLUniversity of Cambridge · GB

Funding

Medical Research Council MC_UU_00025/8
6 · The paper itself

Abstract

The precise regulation of RNA Polymerase II (Pol II) transcription after genotoxic stress is crucial for proper execution of the DNA damage-induced stress response. While stalling of Pol II on transcription-blocking lesions (TBLs) blocks transcript elongation and initiates DNA repair in cis, TBLs additionally elicit a response in trans that regulates transcription genome-wide. Here we uncover that, after an initial elongation block in cis, TBLs trigger the genome-wide VCP-mediated proteasomal degradation of promoter-bound, P-Ser5-modified Pol II in trans. This degradation is mechanistically distinct from processing of TBL-stalled Pol II, is signaled via GSK3, and contributes to the TBL-induced transcription block, even in transcription-coupled repair-deficient cells. Thus, our data reveal the targeted degradation of promoter-bound Pol II as a critical pathway that allows cells to cope with DNA damage-induced transcription stress and enables the genome-wide adaptation of transcription to genotoxic stress.

Indexed as

Glycogen Synthase Kinase 3Transcription, GeneticDNA DamageDNA RepairRNA Polymerase IIGlycogen Synthase Kinase 3RNA Polymerase II

Identifiers

PMID35750669
PMCPMC9232492
OpenAlexW4283457414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.